Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Keating

Showing results (111-120 of 188) with videos related to

Pageof 19
Sort By:
Cancer|March 7, 2006
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemiaMaher Albitar, Steven J Potts, Francis J Giles, et al.
Blood Advances|March 25, 2026
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapyAlexandre Bazinet, Alessandra Ferrajoli, Nitin Jain, et al.
Anesthesia and Analgesia|November 23, 2005
Detection, evaluation, and management of anemia in the elective surgical patientLawrence T Goodnough, Aryeh Shander, Jerry L Spivak, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 22, 2008
Aurora-A kinase nuclear expression in chronic lymphocytic leukemiaKedar V Inamdar, Susan O'Brien, Subrata Sen, et al.
Cancer|February 25, 2003
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndromeJorge Cortes, Hagop Kantarjian, Maher Albitar, et al.
Cancer|March 11, 2003
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromesApostolia Tsimberidou, Elihu Estey, Jorge Cortes, et al.
Cancer|April 5, 2023
Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicityMax J Gordon, Jade E Jones, Binsah George, et al.
Leukemia Research|May 15, 2002
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndromeChung Wu Lin, Taghi Manshouri, Iman Jilani, et al.
Blood|March 23, 2006
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemiaCharles Koller, B Nebiyou Bekele, Xian Zhou, et al.
American Journal of Hematology|February 17, 2015
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcomePreetesh Jain, Michael Keating, Phillip A Thompson, et al.
Pageof 19

Showing results (111-120 of 188) with videos related to

Sort By:
Pageof 19
Cancer|March 7, 2006
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemiaMaher Albitar, Steven J Potts, Francis J Giles, et al.
Blood Advances|March 25, 2026
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapyAlexandre Bazinet, Alessandra Ferrajoli, Nitin Jain, et al.
Anesthesia and Analgesia|November 23, 2005
Detection, evaluation, and management of anemia in the elective surgical patientLawrence T Goodnough, Aryeh Shander, Jerry L Spivak, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 22, 2008
Aurora-A kinase nuclear expression in chronic lymphocytic leukemiaKedar V Inamdar, Susan O'Brien, Subrata Sen, et al.
Cancer|February 25, 2003
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndromeJorge Cortes, Hagop Kantarjian, Maher Albitar, et al.
Cancer|March 11, 2003
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromesApostolia Tsimberidou, Elihu Estey, Jorge Cortes, et al.
Cancer|April 5, 2023
Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicityMax J Gordon, Jade E Jones, Binsah George, et al.
Leukemia Research|May 15, 2002
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndromeChung Wu Lin, Taghi Manshouri, Iman Jilani, et al.
Blood|March 23, 2006
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemiaCharles Koller, B Nebiyou Bekele, Xian Zhou, et al.
American Journal of Hematology|February 17, 2015
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcomePreetesh Jain, Michael Keating, Phillip A Thompson, et al.
Pageof 19